Assembly Biosciences has evolved into a well-funded antiviral development platform, supported by a strategic partnership with Gilead and a strong balance sheet. Its pipeline targets diseases with high unmet needs such as recurrent genital herpes, HDV, and cholestatic liver diseases, showing promising early clinical data. With over $340 million in pro forma liquidity after a recent offering, the company can fund operations through 2028 without needing near-term capital. Despite these strengths and upcoming Phase 2/3 catalysts, Assembly Biosciences trades at a valuation discount compared to peers.
WeRide Inc., a global leader in autonomous driving technology, was recognized as one of China's top 10 AI international collaboration case studies for its autonomous driving deployment in the UAE. It is the only autonomous driving company included, h...
Warren Buffett has given away $6 billion worth of Berkshire Hathaway stock and announced plans to donate an additional $138 billion by 2034. This large-scale philanthropy highlights Buffett's ongoing commitment to charitable causes and his strategy t...
Bitcoin could see a rally pushing prices toward $67,000 and possibly $74,000-$76,000 before a potential sharp decline around the 2026 U.S. midterm elections. Analysts suggest a post-midterm crash could drop Bitcoin to the $51,000-$56,000 range, clear...
Baidu has been upgraded to a HOLD rating as its advertising business faces pressure from China's economic softness, but potential growth in AI and cloud segments offers upside. The stock trades at a forward P/E of 12.3, near its 5- and 10-year lows, ...
ManpowerGroup received a buy rating upgrade following its Q2 2026 results, which showed a 6.1% organic revenue growth, 15% rise in adjusted EBITA, and a 27% increase in adjusted EPS. The company’s Q3 guidance indicates continued strength, supported b...
